Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, gives an overview of the potential of improved techniques for detecting measurable residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML), including next-generation sequencing and digital droplet PCR.
NGS and high sensitivity ddPCR for detecting MRD
